Navigation Links
Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
Date:6/20/2013

New York, New York (PRWEB) June 20, 2013

Byetta pancreatic cancer lawsuit filings continue to mount in courts around the country, Bernstein Liebhard LLP notes that a new investigation by the British Medical Journal (BMJ) has concluded that the pancreatic risks associated with incretin mimetics like Byetta may have been downplayed by the drugs’ manufacturers. According to a report from MedPageToday.com, the BMJ investigation consisted of a review of regulatory documents that discovered unpublished data pointing to “unwanted proliferative or inflammatory pancreatic effects” associated with incretin mimetics. The authors of the report also faulted the U.S. Food & Drug Administration (FDA) and European regulators for failing to aggressively address these concerns.*

“This report just confirms that links between Byetta and pancreatic cancer, as well as pancreatitis, need further review,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta pancreatic cancer lawsuit evaluations to patients who took this drug and were later diagnosed with the disease. Bernstein Liebhard LLP is also investigating claims related to Byetta pancreatitis and thyroid cancer.

Byetta Pancreatic Cancer Lawsuits

Court documents indicate that dozens of Byetta lawsuits have been filed by plaintiffs who suffered pancreatitis and pancreatic cancer, allegedly due to their use of the drug. The U.S. Judicial Panel on Multidistrict Litigation (JPML) will meet on July 25th to hear Oral Arguments regarding the proposed consolidation of all federally-filed personal injury lawsuits involving Byetta and other incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

Concern’s about Byetta’s effects on the pancreas have been mounting since 2008, when the FDA reported that Byetta had been associated with a high number of adverse event reports involving pancreatitis.** In February 2011, research published in Gastroenterology linked the drug to a nearly three-fold increase in the risk for pancreatic cancer, and a six-fold increase in the risk for pancreatitis.*** The same study also reported 30 cases of Byetta thyroid cancer in patients taking the drug. On March 14, 2013, the FDA announced it was investigating findings from an unpublished study that suggested incretin mimetics like Byetta could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.****

On June 10, the American Diabetes Association called for an independent review of Byetta and other incretin mimetics due to the recent controversy. Among other things, the group is requesting that the manufacturers of these medications make patient-level data available on all subjects involved in regulatory trials for such an analysis.*****

Alleged victims of Byetta pancreatic cancer, pancreatitis or thyroid cancer may be entitled to compensation for medical bills and other damages. To learn more about filing a Byetta lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.

*medpagetoday.com/Endocrinology/Diabetes/39803, MedPageToday, June 10, 2013
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008
***gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
****diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html, ADA, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.byettalawsuit2013.com/

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb10854869.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
2. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
3. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
4. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
5. Byetta Lawsuit News: Woman Alleges Her Thyroid Cancer Is Linked to Byetta Use, Rottenstein Law Group LLP Reports
6. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
7. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
8. DrugRisk Announces Launch of Byetta Cancer Resource Center
9. Byetta Pancreatic Cancer Allegation Lawsuits Offered through Resource4thePeople
10. d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
11. Pancreatic Cancer Survivor and Author Bob Brown Releases Highly Anticipated New Book "Ride of My Life"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Overland Park, KS (PRWEB) , ... May 24, ... ... Kansas, announces an expansion of its services to provide one resource, from start ... print reviews and preparation, Life Safety Statement of Condition surveys requested by the ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... is pleased to welcome new Partner Firm Austin & Co., Inc. Headquartered ... to insurance, employee benefits, HR consulting, benefits technology, and beyond. As an ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 ... members of its Advisory Board. Joining the Grow Healthy Advisory ... three of them embody the mission of our organization and bring ... to have them as we continue to expand our footprint as ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Open Access Journal Focusing ... Elsevier , a world-leading provider of scientific, ... the launch of Clinical Neurophysiology ... on clinical practice issues in clinical neurophysiology. The journal ... values and didactic reviews. It is an official journal ...
(Date:5/23/2016)... May 23, 2016 Global Paclitaxel ... pages, profiles 12 companies and the Paclitaxel analysis in ... on the industry and its players. This ... in nature, details the current state of the industry ... definitions, classifications, applications and industry chain structure. The Paclitaxel ...
(Date:5/23/2016)... Clarifying Vision - Prospects and Developments in ... What can be expected from the Ophthalmic ... the fastest rates? This visiongain report shows ... and prospects. ,Our 190-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology: